Improvement of metabolic risk profile under second-generation antipsychotics: A pilot intervention study

Canadian Journal of Psychiatry

Volumn 54, Issue 4, 2009, Pages 275-279

  Blouin, Mélissa ^a,b   Binet, Mario ^c   Bouchard, Roch Hugo ^b,c   Marc André, Roy ^a,b   Després, Jean Pierre ^a   Almeras, Natalie ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

Author keywords

Body weight gain; Intervention study; Metabolic risk profile; Second generation antipsychotics; Weight management

Indexed keywords

CHOLESTEROL; CLOZAPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; AEROBIC EXERCISE; ANTHROPOMETRY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DELUSIONAL DISORDER; EXERCISE; FEMALE; HUMAN; INTERVENTION STUDY; MALE; METABOLIC DISORDER; NUTRITIONAL HEALTH; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PILOT STUDY; PROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CONTROL; WEIGHT REDUCTION;

EID: 65349122975     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370905400409     Document Type: Article

References (29)

1. Meltzer HY. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. J Clin Psychiatry. 2001;62(Suppl 27):35-39.
2. Bouchard RH, Merette C, Pourcher E, et al. Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group. J Clin Psychopharmacol. 2000;20:295-304.
3. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
4. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs. 2004;64:701-723.
5. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70:1-17.
6. Almeras N, Despres JP, Villeneuve J, et al. Development of an atherogenic metabolic risk factor profile associated with the use of a typical antipsychotics. J Clin Psychiatry. 2004;65:557-564.
7. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65(Suppl 7):4-18.
8. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45-53.
9. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.
10. Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence ofthe metabolic syndrome. Can J Psychiatry. 2004;49:753-760.
11. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
12. Brown S, Inskip H, Barraclough B, et al. Causes of the excess mortality of schizophrenia. The unhealthy lifestyle of people with schizophrenia. Br J Psychiatry. 2000;177:212-217.
13. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002;346:591-602.
14. Despres JP, Lamarche B, Bouchard C, et al. Exercise and the prevention of dyslipidemia and coronary heart disease. Int J Obes Relat Metab Disord. 1995;19(Suppl 4):S45-S51.
15. Laaksonen DE, Lakka HM, Salonen JT, et al. Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome. Diabetes Care. 2002;25:1612-1618.
16. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2000;284:3043-3049.
17. Expert Panel on the Identification Evaluation and Treatment of Overweight and Obesity in Adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med. 1998;158:1855-1867.
18. Health Canada. Canada's Food Guide. Ottawa (ON): Ministry ofFood Supply and Services Canada; 1997.
19. Lohman TG, Roche AF, Martorell R. Skinfold thicknesses and measurement technique. Anthropometric standardization reference manual. Champaign (IL): Human Kinetics Books; 1988. p. 55-80.
20. Kline GM, Porcari JP, Hintermeister R, et al. Estimation of V02max from a one-mile track walk, gender, age, and body weight. Med Sci Sports Exerc. 1987;19:253-259.
21. Karvonen MJ, Kentala E, Mustala O. The effects of training on heart rate; a longitudinal study. Ann Med Exp Biol Fenn. 1957;35:307-315.
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
23. Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation. 2000;102:179-184.
24. Loh C, Meyer JM, Leckband SG. A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry. 2006;18:23-31.
25. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898-918.
26. Poirier P, Despres JP. Exercise in weight management of obesity. Cardiol Clin. 2001;19:459-470.
27. Lemieux I, Lamarche B, Couillard C, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med. 2001;161:2685-2692.
28. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881-887.
29. Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001;322:716-720.